Aptevo therapeutics announces $2.75 million offering priced at-the-market under nasdaq rules

Seattle, wa / accesswire / june 28, 2024 / aptevo therapeutics inc. (nasdaq:apvo), a clinical-stage biotechnology company focused on developing novel immune-oncology therapeutics based on its proprietary adaptir™ and adaptir-flex™ platform technologies, today announced that it has entered into securities purchase agreements with certain healthcare-focused and institutional investors to purchase (i) 5,339,806 shares of its common stock or pre-funded warrants in lieu thereof and (ii) warrants to purchase up to an aggregate of 10,679,612 shares of its common stock (the "common warrants") at a purchase price of $0.515 per share and associated common warrant in a registered direct offering priced at-the-market under nasdaq rules. each share of common stock is being offered together with two common warrants, each to purchase one share of common stock.
NDAQ Ratings Summary
NDAQ Quant Ranking